Status:
UNKNOWN
Study of Roxadustat in the Treatment of Acute Myocardial Infarction
Lead Sponsor:
Ruijin Hospital
Conditions:
ST Elevation Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Depite successful primary percutaneous coronary intervention (PCI) and standardized medical treatment, prognosis of acute ST-elevation myocardial infarction patents are still a poor, with high moralit...
Detailed Description
This study is an open-label, paralleled, randomized controlled trial. It aims to evaluate the efficacy and safety of early and short-term administration of roxadustat in the treatment of acute ST-elev...
Eligibility Criteria
Inclusion
- Acute STEMI (ST segment elevation myocardial infarction) diagnosed by ST elevation
- Coronary angiography within 12 hours of symptom onset, with TIMI flow grade 0 - 1 of culprit vessel
- Primary PCI with TIMI flow grade 2 - 3 after successful intervention
- Capable and willing to provide informed consent and capable of completing study visits
Exclusion
- Previous acute myocardial infarction history
- Cardiogenic Shock at admission
- Previously treated by roxadustat
- Contraindications of roxadustat treatment
- Contraindication of Cardiac MRI (e.g. eGFR \< 30 ml/min, pacemaker, metal prosthesis, etc.)
Key Trial Info
Start Date :
June 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2023
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT04803864
Start Date
June 10 2021
End Date
August 31 2023
Last Update
September 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200025